Advertisement

The Scientist

» industry

Most Recent

image: CAR-T Therapies Get $1 Billion Boost

CAR-T Therapies Get $1 Billion Boost

By | July 1, 2015

The biotech firm Celgene inks a huge collaboration deal with Juno Therapeutics to develop and commercialize new cancer immunotherapies.

0 Comments

image: Organ-on-a-Chip Gets Big Pharma Boost

Organ-on-a-Chip Gets Big Pharma Boost

By | June 18, 2015

Johnson & Johnson agrees to use Emulate’s blood-clot device in three of its preclinical drug programs.

0 Comments

image: Follow the Funding

Follow the Funding

By | May 1, 2015

In times of budget belt-tightening at the federal level, life-science researchers can keep their work supported through private sources.  

8 Comments

image: Think Before You Fire

Think Before You Fire

By | May 1, 2015

Industry layoffs may save a few dollars, at the cost of losing the collective brainpower of thousands of scientists.

3 Comments

image: Drugmaker Teva Bids $40 Billion for Mylan

Drugmaker Teva Bids $40 Billion for Mylan

By | April 23, 2015

The Israel-based pharmaceutical company makes an unsolicited offer for a smaller, Netherlands-based rival as its main product faces competition from generics.

0 Comments

image: Another CAR-T IPO

Another CAR-T IPO

By | April 6, 2015

Cellectis goes public for a whopping $228 million—nearly double the value the company filed for in February.

0 Comments

image: 23andMe Enters Drug Development

23andMe Enters Drug Development

By | March 12, 2015

The personal genomics firm announces plans to make medicines.

1 Comment

image: AbbVie Wins Bidding War for Cancer Drugmaker

AbbVie Wins Bidding War for Cancer Drugmaker

By | March 5, 2015

The pharmaceutical firm beat out a host of potential suitors, Johnson & Johnson among them, to strike a $21 billion deal with Pharmacyclics.

0 Comments

image: Pfizer to Acquire Hospira

Pfizer to Acquire Hospira

By | February 5, 2015

The pharmaceutical giant is purchasing the injectable drugmaker for about $15 billion.

0 Comments

image: Lazarus Drugs

Lazarus Drugs

By | February 1, 2015

While some drugs sail through development, others suffer setbacks, including FDA rejections, before reaching the market.  

1 Comment

Advertisement
LI-COR
LI-COR

Popular Now

  1. Opinion: Too Many Mitochondrial Genome Papers
  2. Antibiotics and the Gut Microbiome
  3. Sex Differences in Pain Pathway
  4. The Sum of Our Parts
    Features The Sum of Our Parts

    Putting the microbiome front and center in health care, in preventive strategies, and in health-risk assessments could stem the epidemic of noncommunicable diseases.

Advertisement
Eppendorf
Eppendorf
Advertisement
The Scientist